NEW YORK — OncoDNA said on Tuesday that it has signed an agreement with medical diagnostics services firm Synlab to offer its OncoDeep test for cancer therapy selection in Germany.
Under the terms of the deal, Synlab, which is headquartered in Munich and offers diagnostic services in 36 countries, will perform the OncoDeep cancer sequencing test in its laboratories in Germany to evaluate solid tumors and provide oncologists with treatment decision support. The test covers over 600 cancer biomarkers and measures genomic signatures such as homologous recombination deficiency, tumor mutational burden, microsatellite instability, and loss of heterozygosity. Clinical interpretation will be supported by OncoDNA's database, and patient reports will be made available through the company's OncoKDM online platform.
The companies said that the transfer of the OncoDeep test technology to Synlab, which will manage the entire testing process, is ongoing and that Synlab aims to start processing patient samples in the second quarter.
The deal does not include a license to the OncoDeep technology, an OncoDNA spokesperson said. Financial and other terms of the arrangement were not disclosed.
Earlier this year, OncoDNA, based in Gosselies, Belgium, launched a kit-based version of OncoDeep.